JP2018509151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509151A5 JP2018509151A5 JP2017547412A JP2017547412A JP2018509151A5 JP 2018509151 A5 JP2018509151 A5 JP 2018509151A5 JP 2017547412 A JP2017547412 A JP 2017547412A JP 2017547412 A JP2017547412 A JP 2017547412A JP 2018509151 A5 JP2018509151 A5 JP 2018509151A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- item
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 58
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 230000002068 genetic effect Effects 0.000 claims description 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 102000008579 Transposases Human genes 0.000 claims description 8
- 108010020764 Transposases Proteins 0.000 claims description 8
- 108091008874 T cell receptors Proteins 0.000 claims description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020168936A JP6970991B2 (ja) | 2015-03-11 | 2020-10-06 | トランスポザーゼポリペプチド及びその使用 |
| JP2021173757A JP2022025097A (ja) | 2015-03-11 | 2021-10-25 | トランスポザーゼポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131827P | 2015-03-11 | 2015-03-11 | |
| US62/131,827 | 2015-03-11 | ||
| PCT/US2016/021693 WO2016145146A1 (en) | 2015-03-11 | 2016-03-10 | Transposase polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168936A Division JP6970991B2 (ja) | 2015-03-11 | 2020-10-06 | トランスポザーゼポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509151A JP2018509151A (ja) | 2018-04-05 |
| JP2018509151A5 true JP2018509151A5 (enExample) | 2019-04-18 |
| JP6775515B2 JP6775515B2 (ja) | 2020-10-28 |
Family
ID=55587385
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547412A Active JP6775515B2 (ja) | 2015-03-11 | 2016-03-10 | トランスポザーゼポリペプチド及びその使用 |
| JP2020168936A Active JP6970991B2 (ja) | 2015-03-11 | 2020-10-06 | トランスポザーゼポリペプチド及びその使用 |
| JP2021173757A Withdrawn JP2022025097A (ja) | 2015-03-11 | 2021-10-25 | トランスポザーゼポリペプチド及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168936A Active JP6970991B2 (ja) | 2015-03-11 | 2020-10-06 | トランスポザーゼポリペプチド及びその使用 |
| JP2021173757A Withdrawn JP2022025097A (ja) | 2015-03-11 | 2021-10-25 | トランスポザーゼポリペプチド及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10570382B2 (enExample) |
| EP (2) | EP3268470B1 (enExample) |
| JP (3) | JP6775515B2 (enExample) |
| KR (1) | KR102615825B1 (enExample) |
| CN (1) | CN107532174A (enExample) |
| AU (2) | AU2016229094B2 (enExample) |
| CA (1) | CA2977818A1 (enExample) |
| DK (1) | DK3268470T3 (enExample) |
| ES (1) | ES2854675T3 (enExample) |
| HU (1) | HUE053368T2 (enExample) |
| IL (2) | IL285286B2 (enExample) |
| MX (2) | MX388517B (enExample) |
| PL (1) | PL3268470T3 (enExample) |
| RU (2) | RU2020127887A (enExample) |
| SG (1) | SG11201707111RA (enExample) |
| WO (1) | WO2016145146A1 (enExample) |
| ZA (1) | ZA201706420B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| WO2014186469A2 (en) | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| RU2753965C2 (ru) | 2014-02-14 | 2021-08-24 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Химерные антигенные рецепторы и способы их получения |
| US10570186B2 (en) | 2014-11-05 | 2020-02-25 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) to selectively target protein complexes |
| JP6947647B2 (ja) | 2015-02-24 | 2021-10-13 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 遺伝子改変ｔ細胞の選択方法 |
| RU2020127887A (ru) | 2015-03-11 | 2020-10-02 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Полипептиды транспозазы и их применение |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US10633445B2 (en) | 2015-09-15 | 2020-04-28 | Board Of Regents The University Of Texas System | T-cell receptor (TCR)-binding antibodies and uses thereof |
| WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP7591342B2 (ja) | 2016-06-08 | 2024-11-28 | プレシゲン，インコーポレイテッド | Ｃｄ３３特異的キメラ抗原受容体 |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| CN110462040A (zh) | 2017-01-10 | 2019-11-15 | 英特拉克森公司 | 通过新基因开关表达系统调节多肽的表达 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2019038197A1 (en) | 2017-08-21 | 2019-02-28 | European Molecular Biology Laboratory | IMPROVED TRANSPOSASE POLYPEPTIDE AND USES THEREOF |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| SG11202008539YA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
| KR20200128703A (ko) | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | B형 간염 백신 및 이의 용도 |
| WO2020168086A1 (en) * | 2019-02-13 | 2020-08-20 | Geerlings Maurits W | Nanocarriers for the delivery of nucleic acids and uses thereof |
| JP7769325B2 (ja) * | 2019-07-23 | 2025-11-13 | 株式会社東芝 | Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| US20240316199A1 (en) | 2020-12-30 | 2024-09-26 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5925545A (en) * | 1996-09-09 | 1999-07-20 | Wisconsin Alumni Research Foundation | System for in vitro transposition |
| DE69841648D1 (de) | 1997-03-11 | 2010-06-17 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| EP1232959B1 (de) * | 1999-06-02 | 2004-09-15 | Alcan Technology & Management AG | Kindersichere Verpackung für Tabletten |
| WO2003089618A2 (en) * | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US20060026699A1 (en) | 2004-06-04 | 2006-02-02 | Largaespada David A | Methods and compositions for identification of genomic sequences |
| JP5726522B2 (ja) * | 2007-07-04 | 2015-06-03 | マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン | トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント |
| US20100105140A1 (en) * | 2008-07-16 | 2010-04-29 | Fahrenkrug Scott C | Plaice dna transposon system |
| EP2389435B1 (en) | 2009-01-23 | 2015-11-04 | NsGene A/S | Improved cell lines and their use in encapsulated cell biodelivery |
| WO2012140127A2 (en) * | 2011-04-13 | 2012-10-18 | Immunicum Ab | Method for priming of t cells |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP4029937A1 (en) | 2012-10-04 | 2022-07-20 | Research Development Foundation | Serine protease molecules and therapies |
| WO2014186469A2 (en) * | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| HK1223943A1 (zh) | 2013-05-24 | 2017-08-11 | Board Of Regents, The University Of Texas System | 嵌合的靶向抗原受体的单克隆抗体 |
| KR20160068960A (ko) | 2013-10-25 | 2016-06-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 면역요법을 위한 다클론성 감마 델타 t 세포 |
| RU2753965C2 (ru) | 2014-02-14 | 2021-08-24 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Химерные антигенные рецепторы и способы их получения |
| WO2015164594A1 (en) | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| AU2015249371B2 (en) | 2014-04-24 | 2020-04-30 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| US20170333480A1 (en) | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| US10570186B2 (en) | 2014-11-05 | 2020-02-25 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) to selectively target protein complexes |
| JP6947647B2 (ja) | 2015-02-24 | 2021-10-13 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 遺伝子改変ｔ細胞の選択方法 |
| RU2020127887A (ru) * | 2015-03-11 | 2020-10-02 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Полипептиды транспозазы и их применение |
| US10633445B2 (en) | 2015-09-15 | 2020-04-28 | Board Of Regents The University Of Texas System | T-cell receptor (TCR)-binding antibodies and uses thereof |
| WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
-
2016
- 2016-03-10 RU RU2020127887A patent/RU2020127887A/ru unknown
- 2016-03-10 SG SG11201707111RA patent/SG11201707111RA/en unknown
- 2016-03-10 CN CN201680017179.9A patent/CN107532174A/zh active Pending
- 2016-03-10 ES ES16711096T patent/ES2854675T3/es active Active
- 2016-03-10 KR KR1020177027114A patent/KR102615825B1/ko active Active
- 2016-03-10 RU RU2017134741A patent/RU2735700C2/ru active
- 2016-03-10 EP EP16711096.4A patent/EP3268470B1/en active Active
- 2016-03-10 DK DK16711096.4T patent/DK3268470T3/da active
- 2016-03-10 MX MX2017011679A patent/MX388517B/es unknown
- 2016-03-10 PL PL16711096T patent/PL3268470T3/pl unknown
- 2016-03-10 JP JP2017547412A patent/JP6775515B2/ja active Active
- 2016-03-10 EP EP20204973.0A patent/EP3851523A1/en active Pending
- 2016-03-10 IL IL285286A patent/IL285286B2/en unknown
- 2016-03-10 US US15/556,868 patent/US10570382B2/en active Active
- 2016-03-10 CA CA2977818A patent/CA2977818A1/en active Pending
- 2016-03-10 HU HUE16711096A patent/HUE053368T2/hu unknown
- 2016-03-10 AU AU2016229094A patent/AU2016229094B2/en not_active Ceased
- 2016-03-10 WO PCT/US2016/021693 patent/WO2016145146A1/en not_active Ceased
-
2017
- 2017-09-10 IL IL254394A patent/IL254394B/en unknown
- 2017-09-11 MX MX2021014712A patent/MX2021014712A/es unknown
- 2017-09-22 ZA ZA2017/06420A patent/ZA201706420B/en unknown
-
2020
- 2020-01-14 US US16/742,571 patent/US10883094B2/en active Active
- 2020-04-20 AU AU2020202653A patent/AU2020202653B2/en not_active Ceased
- 2020-10-06 JP JP2020168936A patent/JP6970991B2/ja active Active
- 2020-11-24 US US17/103,500 patent/US11492604B2/en active Active
-
2021
- 2021-10-25 JP JP2021173757A patent/JP2022025097A/ja not_active Withdrawn
-
2022
- 2022-10-26 US US18/049,944 patent/US12116604B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509151A5 (enExample) | ||
| Zander et al. | Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection | |
| RU2017134741A (ru) | Полипептиды транспозазы и их применение | |
| JP7733865B2 (ja) | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 | |
| CN110730821B (zh) | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 | |
| García-Moruja et al. | Functional characterization of SDF-1 proximal promoter | |
| JP2022530653A (ja) | Ｔｅｔ２改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 | |
| Bolinger et al. | Adenoviral vector vaccination induces a conserved program of CD8+ T cell memory differentiation in mouse and man | |
| CN107794272A (zh) | 一种高特异性的crispr基因组编辑体系 | |
| JP2014520551A5 (enExample) | ||
| JP2024133642A (ja) | 活性ｄｎａトランスポゾンシステム及びその使用方法 | |
| JP6022470B2 (ja) | 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法 | |
| JP7728755B2 (ja) | 細胞を再プログラム化して形質細胞様樹状細胞またはｉ型インターフェロン産生細胞に変換する組成物、その方法および用途 | |
| Haertle et al. | Identification of the receptor and cellular ortholog of the Marek's disease virus (MDV) CXC chemokine | |
| KR20220105161A (ko) | 항원 제시를 위해 세포를 2형 수지상 세포 성분으로 재프로그래밍하기 위한 조성물, 그 방법 및 용도 | |
| JP7399871B2 (ja) | Ｔ細胞に高い転写活性を有するキメラプロモーター | |
| CN112899238A (zh) | 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用 | |
| Pfenninger et al. | Naïve primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering | |
| CN104711240B (zh) | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 | |
| CN104672317B (zh) | 调节Oct4基因表达的转录因子ZNF312b及其应用 | |
| Kust et al. | Functional analysis of Drosophila HSP70 promoter with different HSE numbers in human cells | |
| WO2025035508A1 (zh) | 过继性免疫细胞、其制备方法及应用 | |
| CN104762274B (zh) | 禽呼肠孤病毒σNS蛋白及其相关生物材料的应用 | |
| Long et al. | RNAe in a transgenic growth hormone mouse model shows potential for use in gene therapy | |
| CN108884443A (zh) | 用于重组cxadr表达的组合物和方法 |